RE: 05 September new RioGlio/ Pelareorep Article " In this RepGlio study the 24-month survival estimate for all patients was 25.0%, 16.7% for dose level 1 and 33.3% for dose level 2."
By comparison in a 2018 retrosepctive GBM study in a patient population of seventy-seven patients who were treated by multimodality therapy such as surgery plus post-operative radiotherapy (PORT), post-operative Temozolomide (TMZ) concurrent with radiotherapy (CCRT), post-operative CCRT with adjuvant TMZ the overall survival 24 month survival for all patients was 21.3%.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249474/#:~:text=The%20median%20survival%20time%20(MST,were%2021.3%25%20and%2013.8%25.